Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #137 on Allergan Plc (AGN)
DewDiligence
10/16/17 2:04 PM
#138 RE: DewDiligence #137
Allergan plc…today acknowledged that the U.S. District Court for the Eastern District of Texas has issued an adverse trial decision finding that the four asserted patents covering RESTASIS (Cyclosporine Ophthalmic Emulsion) 0.05% are invalid. The Company will appeal the Court's ruling. …The patents include United States Patent Nos. 8,629,111; 8,648,048; 8,685,930 and 9,248,191. These patents, along with United States Patent Nos. 8,633,162 and 8,642,556, are listed in the Orange Book for RESTASIS and expire on August 27, 2024.